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GENETIC AND CLINICAL HETEROGENEITY OF MOYAMOYA DISEASE 
 
LUCA FARRUGIA 
ABSTRACT 
Background: Moyamoya Disease (MMD) is a chronic, occlusive cerebrovascular 
disease characterized by progressive stenosis of intracranial arteries, specifically 
the internal carotid arteries, and the compensatory formation of an abnormal 
vascular network at the base of the brain. The exact cause of MMD is still not 
well understood. Many factors including genetic, environmental, and immunologic 
have been associated with the disease. RNF213 is considered the main 
susceptibility gene, especially in Eastern Asian patients. The founder mutation, 
p.R4810K, has been associated strongly with MMD, especially in Japan and 
Korea but has been shown to have low penetrance and has never been 
described in non-Eastern Asian MMD cases. RNF213 encodes for an E3 
ubiquitin-protein ligase with ATPase activity. It has described to regulate 
angiogenesis giving rise to the possibility that variants in RNF213 may play a role 
in cerebrovascular diseases other than MMD.    
Objectives: The aims of this study were to determine if variation in the RNF213 
gene contributes to MMD in a cohort of 15 unrelated patients with MMD of 
predominantly European descent, to investigate other potential genes implicated 
in MMD in these 15 patients, and to investigate if RNF213 also influences more 
common vascular phenotypes. 
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Methods: Patient history, detailed family history and a blood sample were 
collected from 15 patients with well-characterized MMD.  DNA was extracted 
from a peripheral venous blood sample, assessed for quality, and DNA 
concentration quantified by PicoGreen®. The extracted DNA was sent for whole 
exome sequencing. Genome_GPS_2.0 was used to carry out secondary analysis 
of sequencing data and all data were stored in Oracle TRC. The files were 
aligned using Novoalign, variants analyzed using GATK, visualized using IGV 
and annotated using BioR-Web. Variants of interest were determined using 
Ingenuity® Variant Analysis™. To determine if RNF213 also influences more 
common vascular phenotypes, previously collected and whole exome sequenced 
samples from the Mayo Clinic Florida Familial Cerebrovascular Diseases 
Registry were analyzed. Variants in RNF213 were determined using the same 
approach as for MMD.  
Results: Likely pathogenic variants in RNF213 were found in 13% (2/15) of 
patients. The p.R4810K variant has been previously published as the founder 
mutation for MMD in Eastern Asian populations. The affected patient was also of 
Eastern Asian origin. The other variant, p.R4019C, was found in a European 
descent case and has been described as a candidate pathogenic variant. Eight 
variants in five other genes previously associated with MMD were found. Of 
these, one previously reported variant, p.D455H in RPTN, was found in two 
patients. The other seven have not previously been described in MMD. In the 
analysis of the potential role for RNF213 in other cerebrovascular diseases, 54% 
  vii 
(22/41) of African American patients had a non-synonymous, exonic variant in 
RNF213 with a MAF of less than 3%. A novel RNF213 variant was also found in 
a Caucasian patient who had a subarachnoid hemorrhage.   
Conclusion: The p.R4810K variant in RNF213 was confirmed to only be 
associated with MMD in Eastern Asians and not found in other ethnicities. 
However, a variant in RNF213 was found in a Caucasian patient suggesting 
RNF213 may indeed be disease causing in patients of diverse origin. RNF213 
may also be implicated in other cerebrovascular diseases suggesting a common 
pathogenesis while other genes also appear to be involved in the pathogenesis 
of MMD.  
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INTRODUCTION 
 
 Moyamoya disease (MMD) is a chronic, occlusive cerebrovascular 
disease characterized by progressive stenosis of intracranial arteries, specifically 
the internal carotid artery (ICA), and the compensatory formation of an abnormal 
vascular network at the base of the brain, typically sprouting off the circle of Willis 
(Suzuki 1969). Occlusion of the ICA generally occurs bilaterally, but unilateral 
involvement does not rule out a diagnosis of MMD (Kelly 2006). Although the 
formation of the abnormal vascular network has been considered to be a 
mechanism to compensate for insufficient blood flow through the ICA it is not 
clear that that is the case, as a study has shown that neovascularization can 
precede significant occlusion (Kim 2014). Diagnosis of MMD is commonly made 
first from the appearance of diminished flow in the ICA and additional collateral 
flow on MRI vascular studies. The diagnosis is confirmed on conventional 
catheter-based cerebral angiography, which provides better characterization of 
basal collaterals or “Moyamoya vessels”. Moyamoya syndrome (MMS) is the 
presence of MMD characteristics in conjunction with a different, more well-
defined pathological condition. 
 
Disease History     
In 1957 Moyamoya-like characteristics were first reported in Japan by Dr. 
K. Takeuchi and Dr. K. Shimizu. The term “Moyamoya” was first introduced in 
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1969 by Dr. Jiro Suzuki. The name is Japanese for “a puff of smoke”, chosen 
because of the appearance of the basal collaterals associated with the disease 
on angiogram. The first surgical bypass for a MMD patient occurred in 1972 and 
was performed by Dr. Gazi Yaşargil on a four-year-old boy. The boy’s right-sided 
weakness and speech disturbance was improved at the two-year follow-up 
(Donaghy 1972). 
 
Figure 1: Dr. Jiro Suzuki and One of the Earliest Angiograms of MMD 
(Suzuki 1969) 
 
 
Demographics 
 MMD is primarily seen as an Eastern Asian disease most common in 
Japan, Korea, and China. The incidence in Japan and Korea (1-2 per 100,000 
(Baba 2008, Ahn 2014)) is about 20 times higher than in the U.S. (0.086 overall 
and 0.28 in Asian Americans (Uchino 2005)) and has a prevalence of 10.5-16 per 
100,000 in Japan and Korea (Baba 2008, Ahn 2014). Females are about twice as 
likely to develop MMD as males with a ratio of about 1.9:1 (Ahn 2014). 
Interestingly, MMD presents in a bimodal distribution with peaks of incidence in 
the 1st and 4th decades of life dividing the disease into early and late onset 
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(Figure 2). The increased incidence in females as compared to males is less 
pronounced in the first decade of life than it is in the the second peak in the 
fourth decase. 
 
Figure 2: Bimodal distribution of MMD Incidence and Prevalence (Ahn 2014) 
 
Etiology 
 The exact cause of MMD is still not fully understood. Genetic, 
environmental, and immunologic factors have been associated with MMD. Based 
on inheritance patterns, it is thought to be hereditary and passed on in an 
autosomal dominant manner with incomplete penetrance (Mineharu 2006). About 
10-15% of cases appear to be familial in Japan (Wakai 1997, Baba 2008). Risk 
factors for developing the disease include being of East Asian descent, female, 
age (due to the peaks of onset in the first and fourth decades of life), and 
genomic imprinting as it has been shown that the disease is more likely to 
develop if inherited from the mother (Mineharu 2006).  
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Disease Pathology 
Pathologically MMD presents with intimal thickening in the walls of the 
terminal portions of the ICA bilaterally due to hyperplasia of smooth muscle cells. 
Proliferating intima may also contain lipid deposits. Affected vessels have an 
irregular, wavy elastic lamina, degeneration of media, and decreased diameter. 
Intraluminal thrombi can accompany the intimal thickening creating significant 
arterial occlusion. The anterior, middle, and posterior cerebral arteries that 
emanate from the circle of Willis may also show varying degrees of stenosis or 
occlusion (Takekawa 2004).  
 
Six Angiographic Stages 
 Dr. Suzuki and Dr. Takeuchi proposed 6 stages of MMD progression 
(Table 1). Progression through the stages is commonly observed in children but 
not as frequently in adults. Clinical symptoms do not appear to associate strongly 
with specific stages (Houkin 1996). Along with the minimization of Moyamoya 
vessels characterizing stage 4, sometimes dural and pial collateral vessels begin 
to form.  
Table 1: Suzuki Stages of MMD (Adapted from Suzuki 1969) 
Stages Angiogram Appearance 
1 Narrowing of Terminal ICA (generally bilaterally) 
2 Development of Moyamoya vessels at base of brain  
3 Intensification of Moyamoya vessels and increased ICA occlusion 
4 Diminishment Moyamoya vessels 
5 Reduction of Moyamoya vessels and significant ICA occlusion 
6 Absence of Moyamoya vessels and complete ICA occlusion 
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Early versus Late Onset 
 Ahn et al (2014) demonstrated how the two peaks in age of development 
separate MMD into early and late onset. Early onset MMD develops in the first 10 
years and ischemic symptoms generally predominate. Initial symptoms include 
headaches, hemiplegia, and seizures and tend to lead to transient ischemic 
attacks (TIA) or cerebral infarcts. (Scott 2004). Late onset MMD develops in the 
fourth decade and the typical collateral vessels occur less frequently. Over time 
cerebral perfusion is reduced, which may lead to significant cerebral damage and 
cognitive and neurological decline. Ischemic symptoms predominate in adults, 
but they are significantly more likely to suffer from hemorrhage than children 
(Han 1997).  
 
Treatment 
Currently no pharmacological therapies are available to reverse or halt 
progression of the steno-occlusive arterial changes in MMD as the optimal target 
for intervention is not known. Instead, treatment is aimed at limiting the risk of 
strokes through arterial bypass or the creation of a new blood supply to the 
affected areas of the brain. The commonly used surgical procedures are direct or 
indirect revascularization techniques.  
Direct revascularization techniques involve arterial bypass with the most 
common being a superficial temporal artery – middle cerebral artery bypass 
(STA-MCA). To complete the procedure the surgeon isolates the STA, pulls back 
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the temporalis muscle, makes an incision in the dura, and then creates an 
anastomosis between the STA and MCA (Karasawa 1978). The risk of 
hyperperfusion is relatively high (28%) post-operation and manifests as 
temporary neurologic deterioration (Kim 2008). Direct bypass is less commonly 
done in children due to their small vessel size.  
In contrast, indirect revascularization techniques aim to create an 
environment that promotes angiogenesis in affected regions of the brain. For 
example in Encephalo-duro-arterio-synangiosis (EDAS), opened dura mater is 
flipped into the subdural space to generate more contact between the cortex and 
outer side of the dura, using the middle meningeal artery as the source to form a 
new blood supply (Matsushima 1990). A similar procedure, Encephalo-myo-
synangiosis (EMS), attaches the temporalis muscle directly to the surface of the 
brain and uses the deep temporal artery as the source to form a new blood 
supply (Karasawa 1977). Other indirect methods include multiple burr hole 
surgery, pial synangiosis, and omental transplantation (Kawaguchi 1996, Scott 
2004, Havlik 1992). In certain cases, EDS and EMS procedures are combined to 
maximize the potential for angiogenesis. Direct and indirect techniques have also 
been performed together (Kim 2006). Age, hemorrhagic or ischemic 
presentation, and collateral presence are some of the key factors in determining 
the choice of treatment. The superiority of direct versus indirect revascularization 
techniques on a long term scale is still heavily debated and resolution of the 
issue requires larger studies with longer follow up.  
 7 
Prognosis 
There is no singular prognosis for MMD. In some cases neurologic 
deterioration occurs rapidly while in others the disease develops over decades 
with occasional TIAs. Progression or lack of depends on the extent of occlusion 
and the rate at which it occurs, the formation of basal collaterals which provide 
sufficient blood flow to salvage brain tissue, and the patient’s neurologic state at 
time of treatment. If untreated over half of patients experience significant disease 
progression while fewer than 3% of patients had disease progression after 
surgery. Surgical treatment prior to a major stroke event results in the best 
prognosis. As typical of a progressive disease, untreated patients are likely to 
have further arterial occlusion leading to stroke and mental decline and 
potentially death due intracerebral hemorrhage (Choi 1997, Han 1997, 
Hallemeier 2006). 
 
Genetics of MMD 
Due to its increased prevalence in East Asia, most large-scale genetic 
analysis of MMD has been done in Japan and South Korea. Over the last twenty 
years many candidate genes have been proposed.  
Initially linkage analysis was performed on familial MMD cases to try to 
identify potential chromosomal regions of interest and modes of inheritance. 
Ikeda et al published the first genetic locus study in 1999. In this study 16 
Japanese families (37 MMD patients, 77 individuals total) were reported on. 
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Linkage analysis revealed an association at chromosome 3p24.2-p26 in the 
MMD patients (Ikeda 1999). This region had previously been associated with 
Marfan syndrome and the von Hippel–Lindau disease gene responsible for 
hemangioblastoma. The Ikeda study paved the way for further genetic MMD 
research.  
In 2000 Inoue et al published a MMD study investigating a genetic 
association between the disease and human leukocyte antigens (HLA). The 
linkage analysis performed on 20 affected Japanese sibling pairs found linkage 
to chromosome 6q25 (Inoue 2000). A Korean study (Han 2003) replicated these 
results in 2003. Also in 2000, Yamauchi et al. performed linkage analysis on 24 
Japanese families (56 MMD patients). Because the characteristic bilateral 
terminal occlusion of the ICA typical to MMD has sometimes been seen in 
neurofibromatosis type 1, the study investigated linkage between MMD and 
chromosome 17 (Neurofibromin 1 (NF1) located at chromosome 17q11.2). 
Although no association was found between NF1 and MMD, linkage was shown 
to the telomeric region of chromosome 17q25. Epidermal growth factor receptor-
binding protein 2, integrin-β4 subunit, and tissue inhibitor of metalloproteinase 2, 
all located in adjacent regions of this chromosome, were proposed as candidate 
genes. It was also concluded from this study that the disease is most likely 
inherited in an autosomal dominant fashion with low penetrance (Yamauchi 
2000).  
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In 2004, Sakurai et al investigated 12 Japanese families with 12 sibling 
pairs in a genome-wide linkage analysis (Seven of the 12 families were used in 
the previously described Inoue et al study). Markers on the previously reported 
3p, 6q, and 17q regions with association with MMD did not reach significant 
linkage levels but instead investigators found novel linkage to chromosome 8q13-
24 and suggestive linkage to chromosome 12p13-p12. Transforming growth 
factor-beta-inducible early growth (TIEG), located on 8q was proposed as a 
candidate gene (Sakurai 2004).  
In 2008 Mineharu et al performed genome-wide linkage analysis on 15 
extended Japanese families (53 MMD patients) after identifying the autosomal 
dominant with incomplete penetrance inheritance pattern in these families in 
2006. The study identified a major gene locus on chromosome 17q25.3 that, 
although also in the telomeric region, does not overlap with the 17q25 region 
linked in the Yamauchi 2000 study. Associations in the 3p and 8q regions were 
not replicated. BAIAP2, TIMP2, RAC3, and RAB40B were proposed as candidate 
genes (Mineharu 2008). Liu et al (2010) continued with the work of Mineharu, 
adding two more families to the 15 already included. Linkage analysis 
demonstrated an increased association in the 17q25.3 region. Further 
investigation via fine mapping narrowed signal to a 2.1 Mb region. After 
sequencing and segregation analysis, a single nucleotide polymorphisms (SNP) 
in Raptor (ss161110142 G/A), a gene associated with tissue hypertrophy, 
appeared of greatest interest. A large scale, multiethnic, case-control study 
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investigating this and six other Raptor SNPs was carried out in in Japanese (90 
cases vs. 384 controls), Korean (41 cases vs. 223 controls), Chinese (23 cases 
and 100 controls), and Caucasian (25 cases and 164 controls) populations. The 
study concluded that ss161110142 increased susceptibility to MMD in East Asian 
populations but is not present in the Caucasian samples. 
A breakthrough in the search for a susceptibility gene in MMD came from 
two separate studies in 2011 with the identification of Ring Finger Protein 213 
(RNF213) as the susceptibility gene and p.R4810K as the founder mutation. 
Kamada et al published the first MMD genome-wide association study (GWAS) 
using 72 Japanese patients (64 sporadic cases and 8 probands of MMD families) 
and 45 controls. A strong association was identified in the same 17q25.3 region 
as previously described. Investigating further, a locus-specific association study 
was performed in the 17q25.3 region. This revealed a strong association of SNPs 
in the 3’ end of RNF213. Mutational analysis of RNF213 demonstrated the same 
missense mutation (p.R4810K) in 19 of 20 Japanese MMD families and 46 of 63 
sporadic cases. In Japanese controls, six out of 429 subjects carried this 
mutation while in Caucasians none of the 400 controls or five MMD subjects 
studied was a carrier. As a result of this study, p.R4810K in RNF213 was 
characterized as a founder mutation in MMD.  
 At around the same time, Liu and Mineharu (2011) continued their 
investigation into genetic association in MMD and produced the same results. 
Genome-wide linkage analysis and fine mapping in eight 3-generation families 
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revealed a 1.5 Mb locus in the 17q25.3 region with strong association to MMD. 
After exome analysis in the region and then Sanger sequencing, the variant 
p.R4810K in RNF213 (same as Kamada) was identified with the strongest 
association. The variant was sequenced in East Asian and Caucasian 
populations and found in 145 of 161 (90%) of Japanese cases, 30 of 38 (79%) 
Korean cases, 12 of 52 (23%) Chinese cases, and once again not found in a 
Caucasian population. Five additional variants in RNF213 (p.D4863N, p.E4950D, 
p.A5021V, p.D5160E and p.E5176G) in East Asian cases and four variants 
(p.N3962D, p.D4013N, p.R4062Q and p.P4608S) in Caucasian cases were also 
found. None of the additional nine variants seen were found in controls. All 10 
variants identified were located at the 3’ end of RNF213. The study concluded 
that RNF213 is a susceptibility gene for MMD.  
 Both of these studies noted the low penetrance of the founder mutation in 
MMD. A majority of carriers never develop the disease. It therefore seems likely 
that undiscovered modifiers, genetic and/or environmental, have a significant role 
in disease onset.   
 
RNF213 
RNF213 is now considered to be the main susceptibility gene for MMD, 
especially among Japanese, Korean, and Chinese populations. However, MMD 
does not appear to be a monogenic disorder but instead a disorder resulting from 
the combination of several genetic and environmental factors. It is also possible 
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that unknown genetic modifiers play a significant role in the etiology of MMD. 
This is indicated by the substantially higher prevalence of the p.R4810K variant 
in East Asian populations compared to the actual prevalence of MMD.  
 Structurally the RNF213 protein contains AAA domains associated with 
ATPase activity and a RING finger domain which is a specialized type of Zn-
finger that binds two atoms of zinc (Liu 2011). Functionally RNF213 is an E3 
ubiquitin-protein ligase that potentially plays a role downstream in the non-
canonical Wnt signaling pathway by targeting and degrading NFAT1. This 
pathway is critical for maintenance and remodeling of vasculature. By inhibiting 
NFAT1, RNF213 expressed in endothelial cells appears to prevent the inhibition 
of vessel regression (Scholz 2016).  
 
Figure 3: Proposed Role of RNF213 in Angiogenesis (adaptation of Scholz 
2016) 
 
Liu et al (2011) used a zebrafish model to assess the effect off loss of 
RNF213. Injecting RNF213 morpholinos into early stage zebrafish embryos that 
knocked down gene expression showed abnormal blood vessel sprouting and 
irregular vessel diameter.  
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It is still debated whether p.R4810K causes gain of function or loss of 
function in RNF213, but the consensus seems to be growing that inflammatory 
signals and altered immune response play significant roles in RNF213 
expression and could be the key modifier along with RNF213 mutation in MMD 
(Kobayashi 2015, Ohkubo 2015).  
 
Recent Findings in Multiethnic MMD Populations 
Although the susceptibility variant for MMD, p.R4810K in RNF213, has 
been well described in East Asian populations, it has yet to be seen in any other 
race-ethnic group. Liu et al (2011) described a few other mutations in RNF213 in 
Caucasian MMD subjects but most non-East Asian populations do not display 
mutations in the gene. Therefore other genes need to be explored. Shoemaker et 
al (2015) performed whole-exome sequencing (WES) and case control analysis 
on three population subsets: East Asian/Southeast Asian/Pacific Islander (70 
subjects), Caucasian (136 subjects), and multiethnic non-founder mutation 
carrying (182 subjects). As expected, the founder mutation was only found in 
subjects of East Asian descent. In the Caucasian subset the most significant 
finding was a p.P562L mutation in ZXDC in 14.7% of the cases. The study calls 
the mutation potentially causative for MMD, but notes its relatively high frequency 
in controls (4%) as indication of very low penetrance. Other candidate genes the 
study detected in the Caucasian population included RPTN (p.D110H), CD46 
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(p.A290V), NR3C1 (p.N337S), NAPSA (p.A310T), PDIA4 (p.T173M), and 
IL12RB2 (p.Q426H).  
Kobayashi et al (2015) recently directly sequenced RNF213 in 19 
Slovakian and Czech MMD patients. Once again the founder mutation was not 
seen in a Caucasian population but four other RNF213 variants were identified 
(p.R4019C, p.E4042K, p.V4146A, and p.W4677L).  
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SPECIFIC AIMS 
The role of RNF213 still in MMD is not entirely clear and it seems likely 
that other genes and environmental factors are involved in the pathogenesis. 
Studies have previously shown the strong association of p.R4810K in RNF213 
with MMD in East Asian populations but not in other populations. Other studies 
have described different variants in RNF213 and alternative candidate genes in 
non-Eastern Asian populations that require validation. RNF213 has also recently 
been associated with other cerebrovascular diseases. The extent this gene is 
involved in non-MMD diseases and if it is implicated in all ethnicities is still 
unknown.  
 The purpose of this paper is to determine if variation in the RNF213 gene 
contributes to MMD in a cohort of 15 predominantly Caucasian patients with 
MMD, to investigate other potential genes implicated in MMD in these 15 
patients, and to investigate if variation in RNF213 also influences more common 
vascular phenotypes. 
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METHODS 
Mayo Clinic Registry and Study Eligibility and Enrollment 
Patients with a personal or family history of cerebrovascular disease and 
healthy controls are asked to participate in the Mayo Clinic Florida Familial 
Cerebrovascular Diseases Registry (IRB# 08-003878), which has received 
approval from the Mayo Clinic Institutional Review Board. The primary goal of the 
study is to identify causal gene mutations in cerebrovascular disease and identify 
key relationships between these genes and cerebrovascular conditions. Vascular 
Neurologists prospectively identify patients with one of 23 eligible diagnoses from 
inpatient and outpatient services at Mayo Clinic Florida. Family members are 
encouraged to participate to enhance efforts in identifying pathogenic genes and 
variants. Healthy stroke-free controls are concurrently enrolled. Participants 
enrolled in person have a structured history and physical examination that 
includes assessment of demographic variables, stroke risk factors, stroke 
symptoms, secondary and tertiary diagnoses (if applicable), vital signs, 
neurological impairment (NIH Stroke Scale (NIHSS)), mental status (Mini Mental 
State Exam (MMSE)), and functional status. Stroke symptoms are assessed 
using the 8-item Questionnaire for Verifying Stroke-Free Status.  
Age at time of DNA sample collection, sex, race, and ethnicity are 
recorded. Race and ethnicity were defined according to self-report using 
standard Office of Management and Budget definitions. Country of origin and 
years of education were also noted.  
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The presence or absence of arterial hypertension, diabetes mellitus, atrial 
fibrillation (either chronic or intermittent), cigarette smoking (active or former and 
pack-years), and coronary artery disease (history of myocardial infarction, 
coronary stenting or bypass, and angina pectoris) are recorded. Height, weight, 
blood pressure, and heart rate are measured. Blood pressure is taken from the 
left arm with the patient in a resting state (at least 10 minutes after any physical 
exertion) using a sphygmomanometer. Mid-abdominal circumference was 
measured halfway between the lower border of the ribs, and the iliac crest in a 
horizontal plane (cm).  
Two 10 mL EDTA purple top tubes of venous blood for each consented 
participant are collected. Blood samples are hand-carried from the site of 
collection to the investigator’s laboratory in a sterile, biohazard, sealed container. 
De-identified barcoded samples are stored at -80°C. If a positive family history is 
indicated the relational mySQL database MD running in Linux OS requires a 
Progeny Unique Pedigree Number. Progeny is a relational database in Sybase, 
maintained on a central server to which clients have password-protected access 
(Progeny Software, LLC; http://www.progeny2000.com). The program is used to 
maintain pedigree relationships, along with clinical and genetic data.  
DNA was extracted from the blood, assessed for quality, and re-extracted 
if necessary. DNA integrity was assessed by gel electrophoresis and DNA 
concentration quantified by PicoGreen®. PicoGreen® dsDNA Quantitation 
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Reagent is an ultra-sensitive fluorochrome that selectively binds double-stranded 
DNA (dsDNA) and when bound displays enhanced fluorescence.  
For the purpose of this study, the extracted DNA of 15 unrelated samples 
with a diagnosis of MMD (Table 2) was sent for WES.  
Table 2: Summary of MMD Subject Demographics 
Age:  Average (Min - Max) 39.9 (23 - 58) 
Age at stroke: Average (Min - Max) 34.1 (14 - 54) 
Sex: (M:F) 3:12 
Family History of MMD 2/15 
MMSE: Average (Min - Max) 28.7 (23 - 30) 
NIHSS: Average (Min - Max) 1.3 (0 - 4) 
 
 Data on the role of RNF213 mutations in other cerebrovascular vascular 
diseases was pulled from the previously done WES results of those in the 
Registry.  
 
Whole Exome Sequencing 
  2.1 µg of genomic DNA was used from each proband to perform exome 
sequencing with the Sure Select V4 + UTR exome capture kit (Agilent 
Technologies, Santa Clara, CA, USA) following manufacturer’s standard 
protocol. The sequencing was carried out at the Mayo Clinic Bioinformatics Core 
(Rochester, MN, USA) which performed sequencing on a HiSeq 2000 sequencer 
(Illumina, San Diego, CA, USA). The Mayo Clinic Bioinformatics Core 
(Rochester, MN, USA) also performed alignment and base calling using their 
standard pipelines. 
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Alignment and Variant Calling 
 Genome_GPS_2.0 was used to carry out secondary analysis of 
sequencing data (Figure 4). All data were stored in Oracle TRC. 
 
Figure 4: Genome_GPS 2.0 workflow 
Genome_GPS is the comprehensive secondary analysis pipeline for next-
generation sequencing data at Mayo Clinic. Secondary analysis entails four 
steps: alignment, single nucleotide and small insertion/deletion variant calling, 
structural variation discovery, and annotation. From the Illumina HiSeq platform, 
100 base-pair paired end reads are aligned to hg19 using Novoalign (Novocraft 
Technologies, Malaysia). Quality of sequencing chemistry is evaluated using 
FastQC (Babraham Bioinformatics). After alignment, PCR duplication rates and 
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percent reads mapped on target are used to assess the quality of the sample 
preps. Realignment and recalibration steps are implemented in the Genome 
Analysis Toolkit (GATK) (McKenna 2010). All germline variant calling (both single 
nucleotide and small insertions and deletions) is jointly called through GATK 
Haplotype Caller and GenotypeGVCF walkers. Where possible, samples with 
pedigree files will also undergo PhaseByTransmission to correct potential 
genotype calling errors. Somatic single nucleotide variations (SNVs) are 
genotyped using SomaticSniper (Larson 2012), whereas insertions and deletions 
are called by GATK Somatic Indel Detector (Mckenna 2010). Each variant in 
coding regions are functionally annotated by SnpEff (Cingolani 2012), as well as 
ClinVar (Landrum 2014), dbNSFP (Liu 2011), Online Mendelian Inheritance in 
Man (OMIM) (Hamosh 2005), and the Human Gene Mutation Database (HGMD) 
(Stenson 2013) to predict biological effects. Each variant is also annotated with 
allele frequency from the Exome Aggregation Consortium (Robinson 2015). 
Variants of significant interest are visually inspected using Integrative Genome 
Viewer (Robinson 2011) and then biologically validated using standard molecular 
biology techniques.  Prioritization of mutations for validation (those that are likely 
to have the most dramatic effect on protein function), is based on several factors 
including: how many times a gene was mutated in different cases, how 
deleterious the mutations are likely to be (nonsense mutation versus 
synonymous), etc. SNP annotation was performed with SNP & Variation Suite 
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8.4.2 (Golden Helix Inc., Bozeman, MT, USA). Variants were called according to 
standard nomenclature (den Dunnen 2001). 
 
Variant Filtering 
 After aligning and variant calling, each sample’s data was sent back in a 
variant call format (VCF) file. The VCF files were uploaded into Ingenuity® 
Variant Analysis™ (http://www.ingenuity.com/variants), a commercial variant 
analysis software. This is a program for filtering and prioritizing variants. 
Ingenuity Variant Analysis resulted in generation of a filtered list of the most 
significantly associated genes with each case.   
Starting with 286,143 variants spanning 22,439 genes, variants were kept 
with call quality at least 20 in cases and outside the top 5% most exonically 
variable 100 base regions in healthy public genomes (1000 Genomes). Variants 
are excluded with an observed allele frequency greater than or equal to 3% of 
the genomes in the 1000 genomes project, NHLBI ESP exomes, or ExAC 
Frequency. Variants are kept that are experimentally observed to be associated 
with a phenotype meaning scoring Pathogenic, Possibly Pathogenic or Disease-
associated according to HGMD. Frameshift, in-frame indel, or stop codon change 
or missense variants are kept as well as those that disrupt splice site up to 2 
bases into intronic regions or are predicted to disrupt splicing by MaxEntScan. 
Finally, variants that are known or predicted to affect the inputted “Gene List” are 
kept. 
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The “Gene List” (Table 3) was created by identifying genes from GWAS 
studies on stroke and monogenic disorders that compromised vessel integrity or 
were known to result in stroke or other types of vascular events. 
Table 3: Gene List Used for Filtering 
ABCC6 CD36 EDNRA FUT8 LTBP4 NOTCH2 RBBP8 TGFB3 
ABO CD46 EFEMP2 GDF2 MAP2K1 NOTCH3 RNF213 TGFBR1 
ACE CECR1 ELN GLA MFAP5 NR3C1 ROPN1 TGFBR2 
ACTA2 CLU ENG GUCY1A3 MTCP1 NTM RPTN TREX1 
ACVRL1 CNNM2 EPHX2 HABP2 MTHFR PCNT SH2B3 TTR 
ALDH18A1 COL1A1 F2 HBB MYH11 PDCD10 SKI TWIST1 
APOE COL3A1 F5 HDAC9 MYLK PDIA4 SLC26A11 YY1AP1 
APP COL4A1 FBLN5 HTRA1 NAPSA PHACTR1 SLC2A10 ZFHX3 
ATP7A COL4A2 FBN1 IL12RB2 NCF1 PITX2 SMAD3 ZXDC 
BRCC3 COL5A1 FBN2 JAG1 NF1 PLOD3 SOX17 
 C10orf88 COL5A2  FGA KALRN NFATC2 PRKCH STARD13 
 CBS CRP FGB KL NINJ2 PRKG1 TCF7L2 
 CCM2 CTC1 FOXF2 KRIT1 NOS3 RASA1 TGFB2 
 *Genes highlighted in gray have been previously associated with MMD  
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RESULTS 
Relevant Clinical Information 
Two of the MMD subjects were Asian (Korean and Filipino), one was 
African American, and the remaining 12 were Caucasian. Six of the 15 had an 
ischemic stroke, four had a TIA, eight of the 12 known had family history of 
stroke, nine of the 15 had hypertension, and five of the nine known had family 
history of hypertension.  
Table 4: MMD Patients Clinical Information 
Proband No. Gender Age at Stroke 
Stroke Family 
History 
MMD Family 
History 
Laterality 
1 M 45 No No Bilateral 
2 F 14 No No Bilateral 
3 F 17 Yes Yes Bilateral 
4 F 40 Yes No Unilateral 
5 F 45 Yes Yes Unilateral 
6 F 30 Unknown No Bilateral 
7 F 33 Unknown No Bilateral 
8 M 54 Yes No Unilateral 
9 F 41 Yes No Bilateral 
10 F 37 No No Bilateral 
11 F 20 Yes No Bilateral 
12 M 44 Unknown No Unilateral 
13 F 22 No No Unilateral 
14 F 35 Yes No Bilateral 
15 F 35 Yes No Bilateral 
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Identification of Genetic Variants in MMD Cases 
 WES was performed on all 15 MMD cases to determine associated 
genetic variants. Each sample’s variants were analyzed individually and filtered 
through Ingenuity. Remaining variants were analyzed manually using HGMD, 
OMIM, Alamut, ExAC, and previous research publications in order to determine 
their potential relevance. The effect of the variants on protein function was 
assayed using two prediction algorithms: Polyphen-2 and SIFT both obtained 
from Alamut.  
 
Variants in RNF213 
 A total of 13.3% (2/15) MMD cases two carried mutations in RNF213. A 
total of 8.3% (1/12) Caucasian subjects carried a RNF213 variant. In confirmation 
of the previous literature, the founder mutation p.R4810K in RNF213 was 
identified in the only subject of Eastern Asian ancestry. The geographic region 
specific nature of this mutation was also confirmed, as it was not present in any 
of the other cases including the other Asian American subject who is of Pacific 
Islander descent.    
 The other RNF213 variant found was p.R4019C in a Caucasian subject. 
This variant has been previously described in other Caucasian MMD cases (Liu 
2011, Cecchi 2014, Kobayashi 2016). This variant is very rare, only seen in 
Caucasian and Latino populations and has a minor allele frequency (MAF) of 
less than 0.1%. P.R4019C is predicted to be Probably Damaging and Damaging 
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by PolyPhen-2 and SIFT. Conservation of arginine in position 4019 is seen in 
mammals except rodents.  
 
Significant Non-RNF213 Variants Identified 
 Additional gene variants from genes previously associated with MMD were 
found in IL12RB2 (p.N271Y and p.G465D), NAPSA (p.L408V), PDIA4 (p.D54H), 
RPTN (p.Q459* and p.D455H), and ZXDC (p.A126V and p.A53E) (Table 5).  
Table 5: Significant MMD Variants Identified 
dbSNP Chromosome Gene 
Amino Acid 
Change 
ExAC MAF 
(overall) 
ExAC MAF 
(per ethnicity) 
East Asian 
rs112735431 17 RNF213 p.R4810K 0.04% 0.39% 
rs78198420 1 IL12RB2 p.N271Y 0.05% 0.64% 
Caucasian 
rs139265462 17 RNF213 p.R4019C 0.05% 0.08% 
rs143744326 1 RPTN p.D455H 2.49% 3.59% 
rs189546119 1 RPTN p.Q459* 0.13% 0.03% 
rs2307153 1 IL12RB2 p.G465D 1.41% 2.12% 
rs142692233 3 ZXDC p.A126V 8.93% 20% 
African American 
rs149963292 3 ZXDC p.A53E 1.40% 17.07% 
rs112996264 19 NAPSA p.L408V 0.24% 3.26% 
Pacific Islander 
rs144700814 7 PDIA4 p.D54H 0.06% 0.007% 
  
 The p.D455H mutation in RPTN has been replicated in a previous MMD 
study (Shoemaker 2015) which showed the variant in 14.7% (10/68) of 
Caucasian cases. This study found the variant in 16.7% (2/12) of Caucasian 
cases. P.D455H has a MAF of 3.6% in Non-Finish European (NFE) populations 
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(ExAC) and is predicted to be Benign and Tolerated by PolyPhen-2 and SIFT. 
Conservation of aspartic acid in position 455 is seen in mammals except rodents. 
A novel nonsense mutation (p.Q459*) in RPTN was also found in this study in 
one Caucasian case. P.Q459* is very rare with a MAF of less than 0.1% in NFE 
populations (ExAC) and the glutamine position at 459 is conserved in mammals.    
 The p.N271Y mutation in IL12RB2 has been studied before for its role in 
IL-12 mediated immune response (de Paus 2013) but never shown in a MMD 
case before. This variant was seen in the East Asian subject who also had the 
p.R4810K founder mutation in RNF213. P.N271Y has a MAF of 0.6% in East 
Asian populations and is predicted to be Possibly Damaging and Tolerated by 
PolyPhen-2 and SIFT. The asparagine at position 271 is conserved in mammals 
except canines. Another mutation in IL12RB2 (p.G465D) was found in a 
Caucasian case. P.G465D has a MAF of 2.1% in NFE populations (ExAC) and is 
predicted to be Benign and Tolerated by Polyphen-2 and SIFT. Aspartic acid at 
position 465 has been shown to be tolerated in one species of primate. Both of 
these IL12RB2 mutations are in non-coding RNA (ncRNA) gene regions.  
 Shoemaker et al (2015) found a variant in ZXDC (p.P562L) to be the most 
enriched in Caucasian MMD cases. In this study, two variants in ZXDC, p.A126V 
and p.A53E, were identified in a Caucasian subject and an African American 
subject respectively. Both mutations have relatively high MAF (20% and 17% in 
their respective populations) although this does not entirely rule out the potential 
role of the variants as disease modifiers. P.A126V and p.A53E are predicted to 
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be Benign/Damaging and Benign/Tolerable by Polyphen-2 and SIFT 
respectively. Alanine at position 126 is conserved in mammals and at position 53 
is only conserved in chimps while glutamic acid at this position is tolerated in 
zebrafish. Both of these ZXDC mutations are in ncRNA gene regions. 
 Another variant in a gene (NAPSA, p.L408V) associated with MMD in 
Caucasian samples in the Shoemaker et al (2015) study was found in the African 
American MMD case. P.L408V has a MAF in African populations of 3.3% and is 
predicted to be Benign and Tolerated by PolyPhen-2 and SIFT. Leucine at 
position 408 is conserved in primates.     
 The last gene from the Shoemaker et al (2015) paper that this study 
replicated was in PDIA4. The p.D54H variant was found in the Pacific Islander 
MMD case. This rare variant has a MAF of less than 0.1% in South Asian 
populations and is predicted to be Possibly Damaging and Damaging by 
Polyphen-2 and SIFT. Aspartic acid at position 54 is conserved down to 
roundworms.   
 
RNF213 in Other Vascular Phenotypes 
 Although most notably associated with MMD, RNF213 has been 
associated with other cerebrovascular diseases as well. WES results from 
subjects enrolled in the Mayo Clinic Florida Familial Cerebrovascular Diseases 
Registry were analyzed to investigate this.   
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 A rare, novel variant (p.P1721L) was found in one Caucasian 
subarachnoid hemorrhage (SAH) case. P.P1721L has a MAF of 1.2% in NFE 
populations and is predicted to be Tolerated by SIFT. Proline at position 1721 is 
conserved in mammals as well as in chickens.  
 Multiple RNF213 mutations were found in a cohort of African American 
subjects in the Registry filtered for coding variants at less than 3% ExAC 
frequency in all populations. Of Black/African American, non-Hispanic/Latino 
subjects in the Registry, 53.7% (22/41) had at least one mutation in RNF213. 
Table 6 shows the cases broken down by diagnosis. Of the RNF213 variants 
found in these subjects, five were very rare in African populations, with a MAF of 
less than 0.2%. These five are p.T910M, p.D1067N, p.T1561M, p.H3160R, and 
p.V4804L. Of the variants that received a PolyPhen-2 or SIFT score, three were 
listed as damaging (p.Q469H, p.T910M, and R1983W). P.Q469H was seen in 
five different subjects with varying diagnosis including intracerebral hemorrhage 
(ICH), SAH, definite acute ischemic cerebrovascular syndrome (AICS), and 
unruptured aneurysm. In one SAH case a duplication caused a frameshift 
mutation (c.2008dupC, p.Q670fs*47). A frameshift mutation (p.Glu3806Argfs∗27) 
in RNF213 has previously been associated with intracranial aneurysms in a 
French Canadian population (Zhou 2016). Other RNF213 mutations found in this 
African American cohort include p.M49V, p.P375L, p.N394D, p.T688M, p.V2097I, 
p.R2285T, p.A2443V, p.A2473T, p.G2611R, p.T3243A, p.V3423A, p.D3731G, 
p.R4317Q, p.V4453I, p.I4535T, and p.S4814R. 
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Table 6: African American Cerebrovascular Cases and RNF213 mutation 
Diagnosis No. of cases 
No. of cases with 
variants 
% of cases with 
variants 
Arteriovenous Malformation 2 0 0% 
Carotid Arterial Dissection 2 1 50% 
Definite AICS 15 9 60% 
ICH 4 1 25% 
MMD 1 0 0% 
Perimesencephalic-SAH 2 1 50% 
SAH 11 7 63.6% 
Unruptured Aneurysm 4 3 75% 
Total 41 22 53.7% 
 
A recent GWAS of young onset stroke in Caucasians indicated a 
significant association with two SNPs in SLC26A11 (Cheng 2016). This gene is 
located directly next to RNF213 on chromosome 17q25.3, less than 10kb away. 
Due to the genes close proximity and therefore potentially having significant 
linkage disequilibrium (LD) between their variants, it is possible that RNF213 may 
be associated with these young onset stroke cases. LD analysis showed 
significant linkage between many of the SNPs in SLC26A11 and RNF213 in both 
Central European and Japanese populations. Even though the SNPs are not all 
the same between these populations, the LD patterns in both appeared very 
similar.  
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Figure 5: SLC26A11 Hits in Young Onset Stroke GWAS and Location near 
RNF213 (Cheng 2016) 
  
Figure 6: LD between SLC26A11 and RNF213 in European and Japanese 
populations 
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DISCUSSION 
Research on MMD has identified some significant genes associated with 
the disease, but has yet to fully identify the exact genes and number of genes 
directly implicated in the etiology of MMD. Although most of research has been 
done in Japan and Korea, where the disease is most prevalent, the genetic 
heterogeneity between MMD cases in East Asian and the rest of the world 
indicate that it is important to further investigate the genetics of non-East Asian 
cases. The purpose of this analysis was to validate and explore novel MMD 
related genes in a cohort of mainly non-East Asian subjects as well as to 
examine the role of RNF213 in other cerebrovascular diseases. 
 
Implications of Replicated and Novel Variants in MMD  
The founder mutation in RNF213 with MMD in East Asian patients 
(p.R4810K) and one of the most significantly associated variants in Caucasian 
cases (p.R4019C) were both replicated in this study. The lack of the founder 
mutation in the non-East Asian subjects further supports that this variant is 
specific to the region and not causative in other populations. The presence of 
p.R4019 in a Caucasian MMD case supports the role of RNF213 in MMD in other 
populations, but the lack of significant mutations in this gene found in the other 
13 cases indicates that other genes and factors are likely involved. Sonobe et al 
(2014) demonstrated that RNF213 knockout mice did not develop the 
characteristic Moyamoya abnormal vascular structure therefore also indicating 
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that solely loss of function of RNF213 is not sufficient to generate MMD. 
Kobayashi et al (2015) demonstrated that the combination of overexpression of 
mutated RNF213, p.R4810K and inflammatory signals significantly led to the 
suppression of angiogenesis under hypoxic conditions. 
Variants in two genes involved in inflammatory response, IL12RB2 and 
ZXDC, which had previously been associated with MMD (Shoemaker 2015) were 
replicated in this study. P.N271Y in IL12RB2 found in the East Asian case with 
the founder mutation has been previously described to reduce IL-12 response 
(de Paus 2013). Another variant, P.G465D, was identified in a Caucasian case. 
This mutation has also never been seen in a MMD case before but is located in 
the same exon as another IL12RB2 variant (p.Q426H) that was enriched in 
Caucasian MMD cases (Shoemaker 2015). Functionally the IL12RB2 protein 
binds with IL2RB1 to form the IL-12 receptor (Presky 1996). Receptor binding 
leads to downstream production of interferon-γ which been show to inhibit 
angiogenesis (Sato 1990). This makes combination of founder mutation with the 
IL12RB2 mutation very interesting and the role of this gene in MMD should be 
further explored.  
A variant in ZXDC was the most enriched in Caucasian MMD cases in a 
recent large-scale multiethnic study (Shoemaker 2015). This study identified two 
variants in the gene, in a Caucasian and an African American subject. ZXDC has 
been shown to enhance transcription of MHC Class II genes (Al-Kandari 2007) 
and the absence of said genes leads to dysfunctional immune response (Villard 
 33 
2001). Both mutations identified in ZXDC had very high MAF in their respective 
populations and therefore likely can be ruled out as disease causing.  
 Variants in two genes involved in cytoskeletal organization, RPTN and 
NAPSA, that had been previously associated with MMD (Shoemaker 2015) were 
also replicated in this study. The same variant (RPTN, p.D455H) identified in the 
Shoemaker et al (2015) paper was found in two Caucasian cases in this study. 
The nonsense mutation (p.Q459*), found in separate Caucasian case, is located 
in the same exon as the previously described p.D455H variant. Variation in this 
region of RPTN seems to be associated with MMD in Caucasian cases and 
necessitates further research. The p.L408V mutation in NAPSA appears to be 
less interesting due to its frequency in African populations, benign/tolerated 
predicted scores, and lack leucine of conservation in mammals.  
 The very rare and normally highly conserved variant found in PDIA4 in 
one MMD case could potentially be interesting but as of now its relation to the 
disease does not seem clear.  
 Other non-RNF213 genes that have been previously associated with MMD 
like ACTA2 and GUCY1A3 were not identified in this study. Genes not previously 
associated with MMD were also investigated but with the small sample size, 
none appeared to be especially significant.  
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RNF213 as Risk Factor in More than just MMD 
RNF213 has clearly been identified in association with MMD, but it 
potentially is implicated in other cerebrovascular diseases as well. Recent 
studies have suggested RNF213 is associated with intracranial major artery 
stenosis/occlusion (Miyawaki 2013) and intracranial atherosclerotic stenosis 
(Bang 2015) in East Asian populations and intracranial aneurysms in the French 
Canadian population (Zhou 2016).  Most research on this notion has focused on 
investigating the association of the MMD founder mutation with other 
cerebrovascular diseases in East Asian populations. This study supports the 
potential of RNF213 in non-MMD cases even with non-founder mutations in non-
East Asian patients.  
Large-scale investigation of RNF213 in vascular disease patients of 
African descent has not been attempted, but this study indicates a potential need 
for it. Non-synonymous, exonic mutations of less than 3% MAF in RNF213 were 
found in over half of the subjects and 17% (7/41) displayed multiple variants. 
Based on the expected number of alleles in a cohort of this size due to the MAF 
in African populations (ExAC), four variants could be ruled out as appearing by 
chance (p.G2611R, p.T3243A, p.D3731G, and p.S4814R). This lowers the 
number of cases with at least one RNF213 mutations to 20 (48.8%). One of the 
most interesting variants found (p.Q469H), was present in five cases with four 
different diagnoses. It is predicted to be Probably Damaging by Polyphen-2. 
Further research on this mutation is warranted.  
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Both of the MMD subjects with RNF213 mutations in this study had a 
family history of stroke. It would be interesting to sequence the family members 
with stroke but without MMD for the same mutations. If present then analysis of 
other non-RNF213 mutations solely appearing in the MMD case would be of 
great interest in determining potential modifiers of disease onset.  
  In regards to the LD found between SLC26A11 and RNF213, sequencing 
of RNF213 in young onset stroke patients would be required to determine if the 
gene is truly associated. It is important to note that more highly associated 
regions with young onset stroke were reported than the hits in SLC26A11 in the 
GWAS (Cheng 2016). If RNF213 was found to be associated with young onset 
stroke, it is more likely that it would be in a modifying role as opposed to disease 
causing. Also, even though RNF213 seems like the more likely candidate due to 
its relation with other cerebrovascular diseases, it cannot be ruled out that 
SLC26A11 itself plays a significant role.  
 In the context of clinical and genetic heterogeneity, as sequencing 
continues to become cheaper, increased WES performed on both common and 
rare vascular phenotypes will be essential in elucidating the role of RNF213. 
More data on RNF213 as well as other genes that had previously only been 
associated with rare phenotypes may show that they are implicated in much 
more common diseases as well.  
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Significance of the Genetic Revolution 
The role of genetics in medicine is exponentially growing as the 
technology continues to rapidly advance. This can be seen with the price and 
time it takes for GWAS and WES dropping dramatically and therefore becoming 
more universally viable as research techniques. For MMD and other poorly 
understood heterogeneous diseases, this genetic revolution moves toward not 
only further uncovering disease etiology but also new and more individualized 
treatment options.  
Paired with the expansion of genetics in research are the field’s increasing 
clinical implications. The importance comes with choice of therapeutics and 
selecting individuals for clinical trials. Personalized medicine will introduce a 
treatment or preventative plan that targets an individual’s specific genetic 
variations. For example although a patient may present with a certain phenotype 
pertaining to a disease, the presence of a different disease associated genetic 
variation will lead to a more specified approach than if they had been lumped in 
with everyone with said phenotype. In the same way multiple clinical diseases 
presenting with mutations in the same gene could all be given the same 
therapeutic approach. From this study, the potential role of RNF213 in multiple 
cerebrovascular disorders could result in therapy directed at this specific 
gene/protein pathway in variant carriers. Similarly, the varying genetic landscape 
of MMD patients indicates that there will not be a single drug able to prevent or 
halt vessel occlusion in all cases. An individualized approach seems necessary.  
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 To reach this point of understanding MMD etiology and in turn treatment, it 
is apparent that more research on the genetics of the disease is needed, 
especially in non-East Asian cases.  
  
Study Limitations  
This study, in regard to the genetics of MMD and the role of RNF213 in 
multiple cerebrovascular diseases, is limited by the small sample size and lack of 
controls. In part the small sample size is due to the rarity of the disease, 
especially in the United States. As part of the next step, non-affected family 
members will be sequenced and used as controls. Also, because this study 
utilized WES as opposed to whole genome sequencing, copy number variants 
(CNVs) were not recorded. Another area of concern is that clinical heterogeneity 
of MMD, especially in regard to unilateral cases and the separation of MMD 
cases from MMS.  
  
Implications in Future Research 
Moving forward, continued enrollment and WES of MMD patients at Mayo 
Clinic Jacksonville is necessary to build a more robust database of variants in 
MMD. There are already two more patients enrolled since the original 15 
samples were sent for WES. DNA of non-affected family members is being 
collected and will serve as controls to produce more reliable results. CNV 
analysis may also provide further insight. As the database continues to grow, 
 38 
more in depth statistical analysis can be performed therefore further validating or 
invalidating results.  
 Gaining an understanding of the role of RNF213, an ongoing process, 
requires a multiethnic approach. Currently, nearly all efforts have been focused in 
Japanese and Korean patients. This analysis not only demonstrates the potential 
role of RNF213 in multiple cerebrovascular diseases but also indicates the value 
in research of the gene in non-East Asian populations, including the understudied 
African American population. Clearly more research is needed.  
 The way forward is a global effort. RNF213 is not limited to MMD and 
MMD is not just an Asian disease but a worldwide disorder. A coordinated effort 
is required between clinicians providing high quality imaging for disease 
confirmation and with geneticists continued sequencing on a multiethnic scale. 
Broadening the research of RNF213 to other cerebrovascular diseases will not 
only likely lead to more robust understanding of its function but also in doing so 
will elucidate its role in and the etiology of MMD more clearly. The advancements 
could lead to the development of finely tuned, targeted therapies that would 
enormously benefit patients worldwide.  
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